|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 213.30 EUR | +0.38% |
|
-0.47% | +1.57% |
| 01-13 | SARTORIUS STEDIM BIOTECH : Bernstein maintains a Buy rating | ZD |
| 01-12 | Sartorius AG, Sartorius Stedim Down to Sector Perform as RBC Notes Lower Hiring Activity | MT |
| Capitalization | 20.75B 24.11B 19.24B 18B 33.51B 2,179B 36.04B 222B 87.53B 1,040B 90.11B 88.29B 3,801B | P/E ratio 2025 * |
64.5x | P/E ratio 2026 * | 47.8x |
|---|---|---|---|---|---|
| Enterprise value | 22.83B 26.53B 21.17B 19.8B 36.87B 2,398B 39.65B 245B 96.31B 1,144B 99.14B 97.14B 4,182B | EV / Sales 2025 * |
7.69x | EV / Sales 2026 * | 7.01x |
| Free-Float |
30.28% | Yield 2025 * |
0.38% | Yield 2026 * | 0.49% |
Last Transcript: Sartorius Stedim Biotech
| 1 day | +0.38% | ||
| 1 week | -0.47% | ||
| Current month | +1.57% | ||
| 1 month | +4.61% | ||
| 3 months | +5.28% | ||
| 6 months | +10.58% | ||
| Current year | +1.57% |
| 1 week | 208.4 |  | 219.9 |
| 1 month | 202.7 | | 224 |
| Current year | 206.8 | | 224 |
| 1 year | 148.75 | | 239.8 |
| 3 years | 139.1 | | 358.8 |
| 5 years | 139.1 | | 551 |
| 10 years | 50.1 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 50 | 28/03/2023 |
| Chief Tech/Sci/R&D Officer | 61 | 08/09/2011 | |
Petra Kirchhoff
IRC | Investor Relations Contact | 57 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 07/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 69 | 07/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 68 | 14/09/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.50% | 0.42% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.38% | -0.47% | +8.27% | -33.36% | 24.07B | |
| -1.43% | -3.30% | +7.30% | +7.38% | 212B | |
| -2.26% | -0.79% | +9.85% | +20.42% | 124B | |
| -0.14% | +5.71% | +46.60% | +116.16% | 68.84B | |
| -0.60% | +2.15% | -12.75% | -19.10% | 59.01B | |
| -1.11% | +1.34% | +23.42% | +93.84% | 54.23B | |
| +3.30% | +8.88% | - | - | 36.72B | |
| +0.43% | +3.18% | -17.59% | -36.50% | 27.12B | |
| +0.15% | +4.61% | +28.16% | +34.41% | 26.37B | |
| -1.70% | -2.85% | -24.47% | +24.76% | 20.55B | |
| Average | -0.30% | +1.85% | +7.64% | +23.11% | 65.27B | |
| Weighted average by Cap. | -0.88% | +0.40% | +10.48% | +25.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.97B 3.45B 2.75B 2.58B 4.8B 312B 5.16B 31.81B 12.53B 149B 12.89B 12.63B 544B | 3.23B 3.75B 2.99B 2.8B 5.21B 339B 5.61B 34.58B 13.62B 162B 14.02B 13.73B 591B |
| Net income | 314M 365M 291M 272M 507M 32.99B 546M 3.37B 1.33B 15.74B 1.36B 1.34B 57.55B | 429M 498M 398M 372M 693M 45.04B 745M 4.59B 1.81B 21.5B 1.86B 1.82B 78.57B |
| Net Debt | 2.08B 2.42B 1.93B 1.8B 3.36B 218B 3.61B 22.28B 8.77B 104B 9.03B 8.85B 381B | 1.88B 2.19B 1.75B 1.63B 3.04B 198B 3.27B 20.17B 7.94B 94.37B 8.18B 8.01B 345B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 213.30 € | +0.38% | 46,359 |
| 15/01/26 | 212.50 € | +1.34% | 60,203 |
| 14/01/26 | 209.70 € | -2.33% | 65,764 |
| 13/01/26 | 214.70 € | -0.14% | 50,598 |
| 12/01/26 | 215.00 € | +0.33% | 93,188 |
Real-time Euronext Paris, January 16, 2026 at 07:55 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition